Editorial Commentary
Axillary management in patients with sentinel lymph node micrometastases following neoadjuvant systemic therapy: a call for de-escalation
Translational Breast Cancer Research
2025;
6:
41
(30 October 2025)
Editorial Commentary
Methodological considerations in predicting axillary residual disease using imaging features
Translational Breast Cancer Research
2025;
6:
40
(30 October 2025)
Editorial Commentary
Could circulating tumor cells explain why breast conservation improves survival despite higher locoregional recurrence?
Translational Breast Cancer Research
2025;
6:
39
(30 October 2025)
Editorial Commentary
TARGIT-IORT in early breast cancer—real world evidence for a risk-adapted approach
Translational Breast Cancer Research
2025;
6:
38
(30 October 2025)
Review Article
CHEK2 variants, breast cancer, and implications for management: a narrative review
Translational Breast Cancer Research
2025;
6:
37
(30 October 2025)
Review Article
Precision diagnosis and treatment of PI3K/AKT/PTEN signaling pathway in HR-positive advanced breast cancer: perspectives from Chinese experts
Translational Breast Cancer Research
2025;
6:
36
(30 October 2025)
Review Article
Organoids in breast cancer translational research: intersection of technologies
Translational Breast Cancer Research
2025;
6:
35
(30 October 2025)
Original Article
Patient outcomes and clinician perspectives following one year of ad hoc implementation of neoadjuvant endocrine therapy in early breast cancer
Translational Breast Cancer Research
2025;
6:
34
(30 October 2025)
Original Article
Predictive potential of hepatocyte growth factor and bone morphogenetic proteins in lymphatic metastasis of breast cancer
Translational Breast Cancer Research
2025;
6:
33
(30 October 2025)
Original Article
The impact and mechanisms of CRIP2 on the biological behavior of triple-negative breast cancer cells
Translational Breast Cancer Research
2025;
6:
32
(30 October 2025)
Original Article
Combined treatment of inetetamab plus pyrotinib and vinorelbine in managing advanced HER2-positive breast cancer patients (ILLUMINE): a multicenter, retrospective, real-world study
Translational Breast Cancer Research
2025;
6:
31
(30 October 2025)
Case Report
Multimodality evaluation and ultrasound-guided aspiration of a biopsy-proven inspissated clogged milk duct: a case report
Translational Breast Cancer Research
2025;
6:
30
(30 July 2025)
Editorial Commentary
Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04
Translational Breast Cancer Research
2025;
6:
29
(30 July 2025)
Editorial Commentary
DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer
Translational Breast Cancer Research
2025;
6:
28
(30 July 2025)
Editorial Commentary
Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?
Translational Breast Cancer Research
2025;
6:
27
(30 July 2025)
Editorial Commentary
Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Translational Breast Cancer Research
2025;
6:
26
(30 July 2025)
Mini-Review
Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab
Translational Breast Cancer Research
2025;
6:
25
(30 July 2025)
Review Article
Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies
Translational Breast Cancer Research
2025;
6:
24
(30 July 2025)
Review Article
Escalation and optimisation of primary breast cancer treatment with antibody-drug conjugates
Translational Breast Cancer Research
2025;
6:
23
(30 July 2025)
Original Article
Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses
Translational Breast Cancer Research
2025;
6:
22
(30 July 2025)
Expert Consensus
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2
Translational Breast Cancer Research
2025;
6:
21
(30 July 2025)
Review Article
The role of a national cancer registry in effective implementation and monitoring of the Global Breast Cancer Initiative (GBCI) framework in Ghana: a narrative review
Translational Breast Cancer Research
2025;
6:
20
(30 April 2025)
Review Article
Non-commonly prescribed physical exercises, disciplines and sports in breast cancer survivors: a narrative review
Translational Breast Cancer Research
2025;
6:
19
(30 April 2025)
Review Article
Radiotherapy in breast cancer patients achieving nodal pathologic complete response after neoadjuvant therapy: a scoping review
Translational Breast Cancer Research
2025;
6:
18
(30 April 2025)
Review Article
Preoperative partial breast radiation for favorable early-stage breast cancer: a narrative review
Translational Breast Cancer Research
2025;
6:
17
(30 April 2025)